BridgeBio Oncology net loss widens 98,94% to USD 56,5 juta in Q2 FY26

Reuters2026/08/11 20:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Bridgebio Oncology Therapeutics membukukan rugi bersih kuartal II 2026 melebar menjadi USD 56,5 juta dari USD 28,4 juta setahun sebelumnya.
Beban R&D melonjak 79,56% menjadi USD 49,2 juta, didorong kenaikan biaya uji klinis dan manufaktur untuk BBO-8520, BBO-11818, BBO-10203.
Beban G&A lebih dari quadruple menjadi USD 11 juta, dipicu operasi standalone, transaksi de-SPAC, biaya pesangon satu kali.
Kas, setara kas, sekuritas yang dapat dipasarkan mencapai USD 344,1 juta per 30 Juni 2026; runway pendanaan diproyeksikan hingga 2028.
BBOT memperluas uji kombinasi, termasuk memulai BBO-11818 dengan cetuximab, serta memulai BBO-8520 dengan BBO-10203 pada pasien NSCLC KRASG12C.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bridgebio Oncology Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-344608), on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BridgeBio Oncology net loss widens 98,94% to USD 56,5 juta in Q2 FY26

You may also like

Crypto prices